The global microbiome therapeutics market is anticipated to rise progressively owing to the growing need for precise, reliable, and fast treatment for diseases like phenylketonuria, hepatic encephalopathy, C. difficile infection (CDI), and multidrug resistant urinary tract infection. Orphan drug approvals and advance therapy designation for microbiome therapeutics is expected to fasten the launch of developmental drugs in the microbiome therapeutics market. There is huge potential for growth of this market, as more than 120 candidates drug are in pipeline in different stages of development that will benefit the microbiome therapeutics market.
The global microbiome therapeutics market could be classified on the basis of indication and region. Based on indication, the market is further divided into type 2 diabetes, clostridium difficile infection (CDI), obesity, and primary hyperoxyurea. During the forecast period, C. difficile infection segment is projected to lead the market. Moreover, increasing number of product approval for CDI is expected to increase the number of share held by this segment.
The report offered here gives a phenomenal explanation of how some factors could serve to up the demand in the global microbiome therapeutics market. It also provides useful information about the market segmentation, competitive landscape, and other aspects of the global wireless fetal monitoring systems market.
The results derived from the human microbiome project and other similar studies done on human bacterial symbioses have drawn large attention from applied biomedical research organizations. The human microbiome has led to the identification of 600 microbial reference genome, 60 Mn genes, and sequencing of 700 metagenomes. While MetaHIT catalogue comprises of 3.3 Mn essential human microbiome genes in nearly every set of genes for human gut microbiome. With improved microbiome sequencing capabilities, the global microbiome therapeutics market is expected to flourish during the forecast years. Therefore, this may lead to more research in microbiome sequencing and may discover further diversity of microbiome that will help in finding new and better microbiome therapeutics. Moreover, increasing collaboration between pharmaceuticals companies for developing new drugs may help in generating better drugs that will act as growth aggregator for this market.
North America is envisaged to lead the global microbiome therapeutics market while accounting for a sizable share in the next few years. Development of new therapeutics and rising healthcare expenditure could augur well for the North America microbiome therapeutics market. In addition to that presence of key players in the region has contributed in maintain the dominance in the market.
Europe is also expected to grow considerably in coming years and can hold substantial amount of market share in the global microbiome therapeutics market. However, Asia pacific is expected to grow significantly due to high number of biological research activities in national institutes, increasing economic stability, and rising awareness among physicians concerning new therapeutics in the region.
Some of the major players in the global microbiome therapeutics market are LNC Therapeutics Inc., ViThera Pharmaceuticals Inc., Enterome SA, Ferring B.V., Second Genome Therapeutics, and Vedanta Biosciences Inc. the leading players in the market are expected to invest in strategic alliances and collaborations that help the players to strengthen their position in the market and expand their geographical reach.